The key objective of this project involves the exploration of US rare and endangered plants and their unique host-microbiome community. These communities will be studied for their biosynthesis and production of new classes of natural products (NPs) HCV drug leads with unique MOAs. The project involves a well established collaborative relationship with the laboratories of Prof Mark Hamann and at the University of Mississippi and Tony Whitaker with RFS Pharma and Raymond Schinazi at Emory University/Atlanta VA. The collective expertise provides a unique opportunity to explore new sources for treatments for HCV which are resistant to current forms of treatment.
The specific aims of this program include: 1. A collection and phylogenetic analysis of 100 endangered plant associated bacteria and fungi strains each year. Phylogenetically diverse and unique US endangered plant species (20) will be evaluated for bacteria and fungi which inhibit HCV. This will provide 500 unique bacteria and fungi over the course of the five year project period. 2. Innovative epigenetic tools will be applied to stimulate production of secondary metabolites from silent genes. These will include regulatory tools available commercially as well as those derived from the host endangered plant itself. Each new strain will be subjected to 10 or more epigenetic tools. Highly sensitive HPLC with UV-TOF-ELS detection and small volume NMR will be utilized to evaluate NP production from genes silent under standard culture conditions. 3. A unique HCV real time PCR assay is featured in this grant application as a primary screen to identify extracts obtained from Aim 2 with HCV selectivity for fractionation in aim 4. 4. Active leads from Aim 3 will be purified using HPLC with MS, UV and ELSD detection. Repeated bioassays using real time PCR will be completed until HCV selective metabolites are generated. Natural product structures will be assigned using integrated NMR, HPLC-MS, UV, IR and X-ray crystallographic analysis.
The proposed study is highly relevant to public health and addresses the need for new and better treatments for HCV. Unique natural products from rare/endangered US plants and their associated microbial community will be explored for the potential to control HCV which remains resistant to existing treatments. Hundreds of unusual and rare microbes will be studied using a variety of epigenetic tools to stimulate metabolite expression from silent genes. Pure HCV selective natural products will be evaluated carefully for MOA and activity against drug resistant isolates.
|Yan, Xia; Sims, James; Wang, Bin et al. (2014) Marine actinomycete Streptomyces sp. ISP2-49E, a new source of Rhamnolipid. Biochem Syst Ecol 55:292-295|
|Kasanah, Noer; Farr, Lorelei Lucas; Gholipour, Abbas et al. (2014) Metabolism and resistance of Fusarium spp. to the manzamine alkaloids via a putative retro pictet-spengler reaction and utility of the rational design of antimalarial and antifungal agents. Mar Biotechnol (NY) 16:412-22|
|Li, Huayue; Bowling, John J; Su, Mingzhi et al. (2014) Asteropsins B-D, sponge-derived knottins with potential utility as a novel scaffold for oral peptide drugs. Biochim Biophys Acta 1840:977-84|
|Cox, Daniel G; Oh, Joonseok; Keasling, Adam et al. (2014) The utility of metabolomics in natural product and biomarker characterization. Biochim Biophys Acta 1840:3460-3474|
|Li, Huayue; Su, Mingzhi; Hamann, Mark T et al. (2014) Solution structure of a sponge-derived cystine knot peptide and its notable stability. J Nat Prod 77:304-10|
|He, Yangqing; Peng, Jiangnan; Hamann, Mark T et al. (2014) An iridoid glucoside and the related aglycones from Cornus florida. J Nat Prod 77:2138-43|
|Zhou, Wei; Oh, Joonseok; Wonhwa, Lee et al. (2014) The first cyclomegastigmane rhododendroside A from Rhododendron brachycarpum alleviates HMGB1-induced sepsis. Biochim Biophys Acta 1840:2042-9|
|Yang, Fan; Zou, Yike; Wang, Ru-Ping et al. (2014) Relative and absolute stereochemistry of diacarperoxides: antimalarial norditerpene endoperoxides from marine sponge Diacarnus megaspinorhabdosa. Mar Drugs 12:4399-416|
|Stoddard, Shana V; Hamann, Mark T; Wadkins, Randy M (2014) Insights and ideas garnered from marine metabolites for development of dual-function acetylcholinesterase and amyloid-? aggregation inhibitors. Mar Drugs 12:2114-31|
|Ibrahim, Mohamed Ali; Na, MinKyun; Oh, Joonseok et al. (2013) Significance of endangered and threatened plant natural products in the control of human disease. Proc Natl Acad Sci U S A 110:16832-7|
Showing the most recent 10 out of 14 publications